Wednesday, July 8, 2026

Patent intelligence · US

US 9820991

Pharmaceutical composition comprising brinzolamide

granted A61KA61K31/542A61K47/02A61K47/183
Status granted
Linked drugs 1
Pipeline programs 3
Years to expiry 11
Applicant portfolio 95
Patent details — US 9820991
Jurisdiction
US
Status
granted
Grant date
Nov 21, 2017
Expiration
Nov 16, 2037
Claims
14
CPC classes
A61K, A61K31/542, A61K47/02, A61K47/183
View on Google Patents ↗

Quick answer

US 9820991 (Pharmaceutical composition comprising brinzolamide) is held by SENTISS PHARMA PRIVATE LIMITED. Status: granted. Granted Nov 21, 2017. Expires Nov 16, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
14
CPC classes
A61K, A61K31/542, A61K47/02, A61K47/183, A61K47/186, A61K47/26

More from SENTISS PHARMA PRIVATE LIMITED

Related pharmaceutical patents in our USPTO index.

  1. US 12419895

    Methods for treating subjects with Prader-Willi syndrome

    ESSENTIALIS, INC. · Expires Sep 18, 2045

    granted
  2. US 12350258

    Compositions and methods for treatment of skin-related diseases and promoting dermatological health

    Script Essentials, LLC · Expires Jul 3, 2045

    granted
  3. US 12343348

    Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome

    ESSENTIALIS, INC. · Expires Jun 26, 2045

    granted
  4. US 12343381

    Dosage regimen for pegylated interferon

    PHARMAESSENTIA CORPORATION · Expires Jun 26, 2045

    granted
  5. US 12178823

    Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome

    ESSENTIALIS, INC. · Expires Dec 26, 2044

    granted
  6. US 12109216

    Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome

    ESSENTIALIS, INC. · Expires Oct 3, 2044

    granted
  7. US 12005081

    Chimeric receptors and methods of use thereof

    Senti Biosciences, Inc. · Expires Jun 6, 2044

    granted
  8. US 11884656

    Pyrrole derivatives as PLK1 inhibitors

    SENTINEL ONCOLOGY LIMITED · Expires Jan 25, 2044

    granted

Frequently asked questions

What is US patent 9820991?

US 9820991 (Pharmaceutical composition comprising brinzolamide) is held by SENTISS PHARMA PRIVATE LIMITED. Status: granted. Granted Nov 21, 2017. Expires Nov 16, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9820991?

SENTISS PHARMA PRIVATE LIMITED is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 95 pharmaceutical patents for this assignee.

When does US 9820991 expire?

Our index shows an expiration date of Nov 16, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.